Table 1 The relationship between miR-200a expression and clinicopathologic parameters in patients with breast cancer received preoperative chemotherapy
From: MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer
Clinicopathologic parameters | Number of cases | Median expression of miR-200a (normalized CT)a | P |
|---|---|---|---|
Age,y | 0.731 | ||
≤ 40 | 13 | 10.60 ± 2.870 | |
> 40 | 59 | 10.36 ± 2.939 | |
Histological type | 0.892 | ||
DCIS | 3 | 10.63 ± 1.572 | |
IDC | 69 | 10.39 ± 2.959 | |
Menstrual status | 0.272 | ||
Menstrual | 38 | 10.05 ± 2.514 | |
Menopause | 34 | 10.81 ± 3.285 | |
TNM stage | 0.918 | ||
II | 28 | 10.45 ± 3.601 | |
III | 44 | 10.38 ± 2.412 | |
Tumor size | 0.839 | ||
T1 + T2 | 32 | 10.48 ± 2.639 | |
T3 + T4 | 40 | 10.34 ± 3.138 | |
Chemotherapy response | 0.0021 | ||
PD + SD | 22 | 8.958 ± 2.586 | |
PR | 50 | 11.04 ± 2.835 | |
ER | 0.277 | ||
Negative | 27 | 9.920 ± 2.648 | |
Positive | 45 | 10.69 ± 3.045 | |
PR | 0.501 | ||
Negative | 23 | 10.06 ± 2.166 | |
Positive | 49 | 10.56 ± 3.206 | |
Her2 | 0.515 | ||
Negative | 52 | 10.54 ± 3.049 | |
Positive | 20 | 10.04 ± 2.541 | |
All cases | 72 | 10.40 ± 2.908 |